Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 18;6(2):66.
doi: 10.3390/jof6020066.

Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?

Maria Aigner  1 , Cornelia Lass-Flörl  1
Affiliations
Review

Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?

Maria Aigner et al. J Fungi (Basel). .

Abstract

As the oldest and for many decades the only available agent for the treatment of life-threatening invasive fungal diseases, amphotericin B (AmB) is known for its broad-spectrum fungicidal activity against a wide range of yeasts and molds. However, the main drawback of the present formulations remains its toxicity, the limited use to intravenous administration, and the higher costs associated with the better tolerated lipid formulations. The novel nanoparticle-based encochleated AmB (CAmB) formulation encapsulates, protects, and delivers its cargo molecule AmB in the interior of a calcium-phospholipid anhydrous crystal. Protecting AmB from harsh environmental conditions and gastrointestinal degradation, CAmB offers oral availability in conjunction with reduced toxicity. Matinas BioPharma, Bedminster, NJ is on the way to develop CAmB named MAT2203, currently undergoing Phase II clinical trials.

Keywords: MAT2203; amphotericin B; antifungals; cochleates; oral availability.

PubMed Disclaimer

Conflict of interest statement

MA has received travel grants, honorarium as a speaker, and consultancy fee from Astellas Pharma, MSD, and Gilead. CLF reports support outside the submitted work from Gilead Sciences, Astellas Pharma, Merck Sharp and Dohme, Pfizer, and Basilea.

References

    1. Torrado J.J., Serrano D.R., Uchegbu I.F. The oral delivery of amphotericin b. Ther. Deliv. 2013;4:9–12. doi: 10.4155/tde.12.134. - DOI - PubMed
    1. National Cancer Institute at the National Institutes of Health NCI Drug Dictionary. [(accessed on 22 April 2020)]; Available online: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/793120.
    1. Zarif L. Drug delivery by lipid cochleates. Methods Enzymol. 2005;391:314–329. - PubMed
    1. Matinas Biopharma Matinas BioPharma’s Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations by US FDA. Press Releases 2015. [(accessed on 22 April 2020)]; Available online: https://www.matinasbiopharma.com/media/press-releases/detail/235/matinas....
    1. Zarif L., Graybill J.R., Perlin D., Mannino R.J. Cochleates: New lipid-based drug delivery system. J. Liposome Res. 2000;10:523–538. doi: 10.3109/08982100009031116. - DOI